Paula Martins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4305193/publications.pdf

Version: 2024-02-01

840776 677142 33 560 11 22 citations h-index g-index papers 34 34 34 958 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Awareness about barriers to medication adherence in cardiovascular patients and strategies used in clinical practice by Portuguese clinicians: a nationwide study. International Journal of Clinical Pharmacy, 2021, 43, 629-636.	2.1	6
2	Patient access to gene therapy medicinal products: a comprehensive review. BMJ Innovations, 2021, 7, 123-134.	1.7	8
3	Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution. European Journal of Clinical Pharmacology, 2021, 77, 1397-1407.	1.9	5
4	Defining clinical pharmacy and support activities indicators for hospital practice using a combined nominal and focus group technique. International Journal of Clinical Pharmacy, 2021, 43, 1660-1682.	2.1	7
5	Overtreatment and undertreatment in a sample of elderly people with diabetes. International Journal of Clinical Practice, 2021, 75, e14847.	1.7	3
6	Polypharmacy, potentially serious clinically relevant drugâ€drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacology Research and Perspectives, 2020, 8, e00621.	2.4	21
7	Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1321-1334.	2.5	6
8	The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2019, 155, 107804.	2.8	38
9	Intensive Monitoring Studies for Assessing Medicines: A Systematic Review. Frontiers in Medicine, 2019, 6, 147.	2.6	1
10	Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1719-1728.	2.5	8
11	Diabetes policies and pharmacy-based diabetes interventions in Portugal: a comprehensive review. Journal of Pharmaceutical Policy and Practice, 2019, 12, 5.	2.4	5
12	Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study. Primary Care Diabetes, 2019, 13, 221-232.	1.8	5
13	Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications. Drug Discovery Today, 2019, 24, 823-828.	6.4	22
14	Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal. Patient Preference and Adherence, 2018, Volume 12, 1471-1482.	1.8	4
15	Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 118, 54-62.	4.4	54
16	Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. Frontiers in Medicine, 2017, 4, 182.	2.6	41
17	Rat Aquaporin-5 Is pH-Gated Induced by Phosphorylation and Is Implicated in Oxidative Stress. International Journal of Molecular Sciences, 2016, 17, 2090.	4.1	56
18	Community pharmacists' knowledge and perceptions on risk management plans in the Southern Region of Portugal. Clinical Research and Regulatory Affairs, 2016, 33, 33-38.	2.1	0

#	Article	IF	CITATIONS
19	Non-prescription medicinal products dispensed exclusively in the pharmacy: an underused access opportunity in Portugal?. Drugs and Therapy Perspectives, 2016, 32, 488-498.	0.6	1
20	Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. Primary Care Diabetes, 2015, 9, 482-489.	1.8	17
21	Community pharmacists' attitudes towards adverse drug reaction reporting and their knowledge of the new pharmacovigilance legislation in the southern region of Portugal: a mixed methods study. Drugs and Therapy Perspectives, 2015, 31, 316-322.	0.6	17
22	Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. European Journal of Health Economics, 2013, 14, 875-885.	2.8	22
23	Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal. BMC Musculoskeletal Disorders, 2013, 14, 279.	1.9	10
24	Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention. International Journal of Clinical Pharmacy, 2012, 34, 699-709.	2.1	6
25	Preventable drug-related morbidity in community pharmacy: commentary on the implications for practice and policy of a novel intervention. International Journal of Clinical Pharmacy, 2012, 34, 682-685.	2.1	4
26	Effect of reminder cards on compliance with antihypertensive medication. International Journal of Pharmacy Practice, 2010, 13, 205-211.	0.6	13
27	Acceptability of Community Pharmaceutical Care in Portugal: A Qualitative Study. Journal of Health Services Research and Policy, 2010, 15, 215-222.	1.7	11
28	Erro médico: Community pharmacists and physicians inter-professional work: insights from qualitative studies with multiple stakeholders. Revista Portuguesa De ClÃnica Geral, 2010, 26, 590-606.	0.0	7
29	[Preventable drug-related morbidity: determining valid indicators for primary care in Portugal]. Acta Medica Portuguesa, 2007, 20, 107-29.	0.4	5
30	Asthma Mortality in Portugal. Treatments in Respiratory Medicine, 2006, 5, 143-147.	1.4	4
31	Prevalence of Self-medication in Rural Areas of Portugal. International Journal of Clinical Pharmacy, 2006, 28, 19-25.	1.4	46
32	How to measure (or not) compliance to eradication therapy. Pharmacy Practice, 2006, 4, 88-94.	1.5	2
33	Selfâ€medication in a Portuguese urban population: a prevalence study. Pharmacoepidemiology and Drug Safety, 2002, 11, 409-414.	1.9	103